Immunovant, Inc.
IMVT
$31.46
-$0.15-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -38.90% | 0.44% | -15.93% | -38.40% | -41.33% |
| Total Depreciation and Amortization | -11.93% | 2.02% | 17.98% | 33.75% | 70.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -4.63% | 9.12% | 5.25% | 37.08% | 17.90% |
| Change in Net Operating Assets | 359.49% | 624.35% | 36.93% | -482.60% | -384.55% |
| Cash from Operations | 14.08% | 8.03% | -15.64% | -54.08% | -85.32% |
| Capital Expenditure | 96.02% | -- | -- | -- | -34.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 96.02% | -- | -- | -- | -34.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.21% | 22,837.87% | 3,269.18% | 325.36% | 29,086.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 125.71% | -- | -- | -- | -- |
| Cash from Financing | -99.19% | 22,814.08% | 3,269.18% | 325.36% | 29,065.83% |
| Foreign Exchange rate Adjustments | -102.46% | 353.02% | -16.30% | -268.96% | -117.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -127.24% | 581.04% | 11.51% | -52.68% | 710.53% |